Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 301–400 of 932
The Molecular Pathogenesis of Multiple Myeloma
Bolli, N., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.9054 · Cited by 25
Huber, J. H., Ji, M., Shih, Y.-H., Wang, M., Colditz, G. A., & Chang, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41223-8 · Cited by 26
“First, we lacked data on smoldering multiple myeloma (SMM), an intermediate state betweenMGUSandMM,soweareunabletoassesshowprogressionto SMM varies across age, gender, and race/ethnicity 25 .”
Mouhieddine, T. H., Nzerem, C., Redd, R. A., Dunford, A. J., Leventhal, M. J., Sklavenitis‐Pistofidis, R., Tahri, S., El‐Khoury, H., Steensma, D. P., Ebert, B. L., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0093 · Cited by 22
Óskarsson, J. Þ., Rögnvaldsson, S., Þorsteinsdóttir, S., Aspelund, T., Gunnarsson, S. B., Hákonardóttir, G. K., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Gíslason, G. K., Ólafsson, A., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00951-2 · Cited by 23
From MGUS to multiple myeloma: Unraveling the unknown of precursor states
Hevroni, G., Vattigunta, M., Kazandjian, D. G., Coffey, D. G., Diamond, B. T., Maura, F., Hoffman, J., & Landgren, O. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101242 · Cited by 25
Kumar, S. K., Dingli, D., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07069.x · Cited by 22
“SMM represents an intermediate stage with very high rate of development of symptomatic MM and these patients often have few bone lesions and mild anaemia (Rosinol et al, 2003; Kyle et al, 2007).”
BackgroundResultSelf-citationPerspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 25
“Nonetheless, those patients, who did not seem to show benefit from early treatment with conventional chemotherapy [1,59,60], may be candidates for clinical trials investigating experimental approaches such as lenalidomide, or other agents with low toxicity administered with the aim to delay the progression in this set…”
BackgroundRole of Positron Emission Tomography/Computed Tomography in Bone Malignancies
Peller, P. J. (2013) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2013.05.005 · Cited by 22
“Patients with SMM convert to MM at a rate of approximately 10% per year for the first 5 years.(86,87) Patients with MGUS are detected incidentally on routine laboratory tests.”
BackgroundThe Role of Early Intervention in High-Risk Smoldering Myeloma
Joseph, N. S., Dhodapkar, M. V., & Lonial, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278915 · Cited by 23
Matsuyama, Y., Nagashima, T., Honne, K., Kamata, Y., Iwamoto, M., Okazaki, H., Sato, K., Ozawa, K., & Minota, S. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4636 · Cited by 22
“However, about 60% of patients with smoldering disease eventually develop symptomatic MM, and the IgA-type generally progresses most swiftly (8, 9).”
BackgroundRajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.23204 · Cited by 24
“Even SMM poses similar problems since on average patients have a 50% likelihood of being progression free 5 years from the date of diagnosis [10].”
BackgroundSelf-citationSerum Free Light Chain Assay in Monoclonal Gammopathic Manifestations
Lee, W. S., & Singh, G. (2019) · Laboratory Medicine · doi:10.1093/labmed/lmz007 · Cited by 22
MYC inhibitors in multiple myeloma
Martínez-Martín, S., & Soucek, L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.55 · Cited by 27
New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies
Kapoulas, S., Raptis, V., & Papaioannou, M. (2015) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2014.12.005 · Cited by 23
Kazandjian, D. G., Mailankody, S., Korde, N., & Landgren, O. (2014) · PubMed · Cited by 23
Lee, S. Y., Kim, H.-J., Shin, Y. R., Park, H.-J., Lee, Y., & Oh, S. J. (2016) · European Radiology · doi:10.1007/s00330-016-4543-8 · Cited by 22
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
Blimark, C. H., Vangsted, A. J., Klausen, T. W., Gregersen, H., Szabo, A. G., Hermansen, E., Wålinder, G., Knut‐Bojanowska, D., Zang, C., Turesson, I., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13707 · Cited by 23
Maatouk, I., He, S., Becker, N., Hummel, M., Hemmer, S., Hillengaß, M., Goldschmidt, H., Hartmann, M., Schellberg, D., Herzog, W., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021376 · Cited by 21
“It is regularly preceded by asymptomatic stages namely monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma (SMM) with a risk of progression of approximately 1% and 10% per year, respectively.(1) 2 As a result of improvements in therapeutic interventions such as high-dose chemothe…”
BackgroundNadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55308-5 · Cited by 20
Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy
Rodríguez-García, A., Ancos-Pintado, R., García-Vicente, R., Ortiz-Ruiz, A., Arroyo, A., Navarro, M. A., Morales, M. L., Guevara‐Ramírez, P., Justo, P., López‐Muñoz, N., et al. (2025) · Microbiome · doi:10.1186/s40168-025-02045-6 · Cited by 20
“MM is a progressive disease that is preceded by an asymptomatic stage known as monoclonal gammopathy of undetermined significance (MGUS) and also often by an intermediate stage known as smoldering myeloma (SMM) [1–5].”
Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma
Zorlu, T., Kayer, M. A., Okumus, N., Ulaş, T., Dal, M. S., & Altuntaş, F. (2025) · Diagnostics · doi:10.3390/diagnostics15131708 · Cited by 22
“Other features typically noted are neuropathy, developing infections (recurrent), loss of weight (involuntary), and easy bruising/bleeding [13].”
Multiple Myeloma: Updates on Diagnosis and Management.
Jewell, S. W., Xiang, Z., Kunthur, A., & Mehta, P. (2015) · Europe PMC (PubMed Central) · Cited by 24
Dilemmas in Treating Smoldering Multiple Myeloma
Ahn, I. E., Mailankody, S., Korde, N., & Landgren, O. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.4351 · Cited by 20
“For current clinical practice, we strongly recommend that patients with SMM who meet prospectively validated high-risk categories be considered for clinical trials.(2,4-6,40) In our opinion, patients with SMM should not be treated outside clinical trials until data from treatment trials mature to give more information.”
BackgroundMethodManzoni, M., Pompa, A., Fabris, S., Pelizzoni, F., Ciceri, G., Seia, M., Ziccheddu, B., Bolli, N., Corradini, P., Baldini, L., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000402 · Cited by 20
“The risk of transforming from SMM to MM is more heterogeneous.(1) Several risk factors have been identified to predict SMM progression at diagnosis, and scorers have been proposed to identify high-risk patients with >50% risk at 2 years.”
BackgroundMagnano, L., de Larrea, C. F., Elena, M., Cibeira, M. T., Tovar, N., Aróstegui, J. I., Pedrosa, F., Rosiñol, L., Filella, X., Yagüe, J., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.034 · Cited by 20
Atrash, S., Robinson, M. M., Slaughter, D., Aneralla, A., Brown, T., Robinson, J., Ndiaye, A. P., Sprouse, C., Zhang, Q., Symanowski, J. T., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0144-x · Cited by 20
Molecular Pathogenesis of Multiple Myeloma
Maura, F., & Bergsagel, P. L. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.010 · Cited by 19
Presentation and risk stratification – improving prognosis for patients with multiple myeloma
Lonial, S. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70007-4 · Cited by 24
New Approaches to Smoldering Myeloma
Mateos, M., & Miguel, J. F. S. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0174-1 · Cited by 21
“The annual risk of progression from SMM to symptomatic MM is 10 % per year for the first 5 years, 5 % per year during the following 5 years and only 1 % per year after 10 years [5].”
BackgroundConsiderations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 21
“The overall risk of progression to symptomatic or active MM reaches a 78% probability at 20 yr (6) A few small, randomised trials in the early 1990s observed no difference in overall survival (OS) between melphalan plus prednisone (MP) chemotherapy and observation (7), and established the current standard of care base…”
BackgroundChrzan, R. M., Jurczyszyn, A. J., & Urbanik, A. (2017) · Polish Journal of Radiology · doi:10.12659/pjr.901742 · Cited by 21
Smoldering Multiple Myeloma: To Treat or Not to Treat
Kapoor, P., & Rajkumar, S. V. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000350 · Cited by 21
Self-citationZhao, A., Shen, K., Wang, J., Huo, L., Li, J., & Cao, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s205623 · Cited by 20
Immunotherapy of Multiple Myeloma: Promise and Challenges
Abramson, H. N. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s306103 · Cited by 21
Gjeorgjievski, M., Purohit, T., Amin, M., Kurtin, P. J., & Cappell, M. S. (2015) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2015/320120 · Cited by 19
“SMM is far more likely to progress to MM or amyloidosis than MGUS (78% versus 21% risk of progression) [4].”
Self-citationHost-related immunodeficiency in the development of multiple myeloma
Dosani, T., Mailankody, S., Korde, N., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., Kwok, M., Kazandjian, D. G., Costello, R., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1361026 · Cited by 20
“Similar trends for B and T cells were observed when SMM cohort was risk stratified using Mayo Clinic model or using immunoparesis (data not shown).”
MethodResultInfluentialWennmann, M., Kintzelé, L., Piraud, M., Menze, B. H., Hielscher, T., Hofmanninger, J., Wagner, B., Kauczor, H., Merz, M., Hillengaß, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25402 · Cited by 19
“Thus, based on the estimation that 20% of SMM patients progress in the first 2 years [2], this results in a sensitivity of approximately 15%.”
BackgroundDifferential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain, M., Yellapragada, S. V., & Hadidi, S. A. (2023) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s272703 · Cited by 27
“The median age of SMM onset is 67 years, with a high prevalence among Black individuals.(21) Black individuals have a lower risk of progression to MM in both univariate (HR 0.”
Lee, W. S., & Singh, G. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3383w · Cited by 21
“Neoplastic plasma cell disorders are classified into three groups, namely, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and multiple/ plasma cell myeloma (MM) in increasing order of severity, with plasma cell myelomas reflecting a malignant progression of the former [3,…”
BackgroundCirculating microRNAs and Their Role in Multiple Myeloma
Federico, C., Sacco, A., Belotti, A., Ribolla, R., Cancelli, V., Giacomini, A., Ronca, R., Chiarini, M., Imberti, L., Marini, M., et al. (2019) · Non-Coding RNA · doi:10.3390/ncrna5020037 · Cited by 19
“The risk of progression from MM to SMM is around 10% per year for the first five years, 5% per year during the subsequent five, and 1% per year for the following 10 years thereafter [9,10].”
BackgroundInfluentialKhouri, J., Faiman, B. M., Grabowski, D., Mahfouz, R. Z., Khan, S. N., Wei, W., Valent, J. N., Dean, R. M., Samaras, C. J., Jha, B. K., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.004 · Cited by 18
Wennmann, M., Goldschmidt, H., Mosebach, J., Hielscher, T., Bäuerle, T., Komljenovic, D., McCarthy, P. L., Merz, M., Schlemmer, H., Raab, M. S., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18232 · Cited by 18
The consultant's guide to smoldering multiple myeloma
Þorsteinsdóttir, S., & Kristinsson, S. Y. (2022) · Hematology · doi:10.1182/hematology.2022000355 · Cited by 18
Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?
Bianchi, G., & Ghobrial, I. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.009 · Cited by 19
de Macedo, S. R. B., de Lima, L. A. R., de Torres, S. M., de Oliveira, V. V. G., de Morais, Peixoto, C. A., Tenório, B. M., & Junior, V. A. D. S. (2018) · Veterinary World · doi:10.14202/vetworld.2018.649-656 · Cited by 17
Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
Jiang, Q., Mao, H., He, G., & Mao, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215791 · Cited by 18
Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
Rago, A., Grammatico, S., Zà, T., Levi, A., Mecarocci, S., Siniscalchi, A., Rosa, L. D., Felici, S., Bongarzoni, V., Piccioni, A. L., et al. (2012) · Cancer · doi:10.1002/cncr.27657 · Cited by 18
“This risk is estimated at 10% per year during the first 5 years.(1-4) Progression represents the most serious clinical problem of patients with SMM.”
BackgroundResultSasseville, V. G., Mansfield, K. G., Mankowski, J. L., Tremblay, C., Terio, K. A., Mätz‐Rensing, K., Gruber-Dujardin, E., Delaney, M. A., Schmidt, L. D., Liu, D., et al. (2012) · Veterinary Pathology · doi:10.1177/0300985812461655 · Cited by 17
“This animal had asymptomatic monoclonal hyperglobulinemia approximately 2 years prior to presentation, which is consistent with monoclonal gammopathy of unknown significance (MGUS) or smoldering (asymptomatic) multiple myeloma (SMM).(3,35) In humans, multiple factors, including MGUS or SMM, are considered risk factors…”
State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias
Amini, B., Yellapragada, S. V., Shah, S. N., ROHREN, E. M., & Vikram, R. (2016) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2015.12.008 · Cited by 18
Princic, N., Gregory, C. M., Willson, T. M., Mahue, M., Felici, D., Werther, W., Lenhart, G. M., & Foley, K. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00224 · Cited by 17
“Smoldering MM, often referred to as “early MM,” has a risk of progressing of 10% per year for the first 5 years, 3% per year for the next 5 years, and 1–2% per year for the next 10 years (11, 12).”
BackgroundSmoldering Multiple Myeloma: Who and When to Treat
Mateos, M., & González‐Calle, V. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.022 · Cited by 18
“The annual risk of progression from SMM to symptomatic MM is 10% per year for the first 5 years, 5% per year during the following 5 years, and only 1% per year after 10 years.(11) Although most patients diagnosed with SMM will progress to symptomatic MM and will need to start treatment, SMM is not a uniform disorder.”
BackgroundBahuaud, M., Bodilis, H., Malphettes, M., Maugard, A., Matondo, C., Bouscary, D., Batteux, F., Launay, O., & Fermand, J. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00441 · Cited by 17
State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill, E., Dew, A., & Kazandjian, D. G. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.03.001 · Cited by 17
Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
Bosseboeuf, A., Seillier, C., Mennesson, N., Allain‐Maillet, S., Fourny, M., Tallet, A., Piver, É., Lehours, P., Mégraud, F., Berthelot, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00854 · Cited by 17
“LGL1-specific immunoblotting assays were performed as described in the Materials and Methods section (7, 27, 28).”
MethodGenomic profiling to contextualize the results of intervention for smoldering multiple myeloma
Kazandjian, D., Diamond, B., Papadimitriou, M., Hill, E., Sklavenitis-Pistofidis, R., Ziccheddu, B., Blaney, P., Chojnacka, M., Durante, M., Maclachlan, K., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0210 · Cited by 16
Setayesh, S. M., Ndacayisaba, L. J., Rappard, K. E., Hennes, V., Rueda, L. Y. M., Tang, G., Lin, P., Orlowski, R. Z., Symer, D. E., Manasanch, E. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00446-0 · Cited by 18
“These lead to high tumor burden and organ damage and include MM, relapsed/refractory MM (RRMM), and either primary or secondary plasma cell leukemia (PCL) 2 – 5 .”
Lenalidomide in multiple myeloma: current role and future directions
Zeldis, J. B., Knight, R., Jacques, C. J., Tozer, A., & Bizzari, J.-P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003645611 · Cited by 16
“patients must have a proportion of aberrant plasma cells within the total plasma cell bone marrow compartment by immunophenotyping of ‡ 95% plus immunoparesis [73-76].”
BackgroundIdentify multiple myeloma stem cells: Utopia?
Saltarella, I., Lamanuzzi, A., Reale, A., Vacca, A., & Ria, R. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.84 · Cited by 20
Multiple myeloma: managing a complex blood cancer
Dowling, M., Kelly, M. L., & Meenaghan, T. (2016) · British Journal of Nursing · doi:10.12968/bjon.2016.25.s18 · Cited by 18
Proteomics-inspired precision medicine for treating and understanding multiple myeloma
Ho, M., Bianchi, G., & Anderson, K. C. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1732205 · Cited by 16
“Another study utilized MASS-FIX to identify MGUS or SMM patients at risk of developing LC amyloidosis [152].”
BackgroundInfluentialImmunomodulation as a therapeutic strategy in the treatment of multiple myeloma
Mitsiades, C. S., & Chen‐Kiang, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.014 · Cited by 16
An old drug with a new future: bendamustine in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Vigna, E., Martino, M. V., Morabito, L., Lucia, E., Bossio, S., Stefano, L. D., Granata, T., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.837885 · Cited by 17
“Nonetheless, those patients, who did not seem to show benefit from early treatment with conventional chemotherapy [1,19,20], may be candidates for clinical trials investigating experimental approaches such as lenalidomide, or other agents with low toxicity administered with the aim of delaying progression in this sett…”
BackgroundEmerging biological insights and novel treatment strategies in multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., & Morabito, F. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.713345 · Cited by 19
“Moreover, those patients did not show benefit from early treatment with conventional chemotherapy [1,45,46], while, it is currently under evaluation whether IMiDs are able to delay the progression in this setting.”
BackgroundSmoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Blum, A., Bazou, D., & O’Gorman, P. (2018) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s136447 · Cited by 17
“20,32 23 Sørrig et al 27 recently reported that immunoparesis and M-protein levels of > 30 g/L can significantly affect TTP to MM. 27”
InfluentialLe, G. N., Bones, J., Coyne, M., Bazou, D., Dowling, P., O’Gorman, P., & Larkin, A. (2019) · Molecular Omics · doi:10.1039/c8mo00193f · Cited by 18
Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
Kim, E. B., Yee, A. J., & Raje, N. S. (2020) · Cancers · doi:10.3390/cancers12051223 · Cited by 17
“Median TTP shortened with an increasing extent of bone marrow involvement with bone marrow plasma cells <20%, 20–50%, and >50% being associated with median TTP of 117, 26, and 21 months, respectively [2].”
BackgroundInfluentialSingh, G., Savage, N. M., Jillella, A. P., & Bollag, R. J. (2020) · Laboratory Medicine · doi:10.1093/labmed/lmab054 · Cited by 19
Weiss, B. M., & Kuehl, W. M. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.13 · Cited by 17
Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus
(2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50018-3 · Cited by 20
Cárdenas, M. C., García‐Sánz, R., Puig, N., Pérez-Surribas, D., Flores-Montero, J. A., Ortiz-Espejo, M., de la Rubia, J., & Cruz-Iglesias, E. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0326 · Cited by 19
Chan, P. C., & Chen, J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.03.014 · Cited by 15
Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders
Chatterjee, G., Gujral, S., Subramanian, P. G., & Tembhare, P. R. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0822-z · Cited by 16
Glomerular and Tubulointerstitial Diseases
Beck, L. H., & Salant, D. J. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.01.002 · Cited by 19
Multiple myeloma: the disease and its treatment
Gupta, M., Pal, R. N., & Tikoo, D. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130302 · Cited by 17
Madan, S., & Greipp, P. R. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.07.004 · Cited by 18
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14
“MGUS and SMM can be detected by serum protein electrophoresis more than 10–15 years before myeloma diagnosis 5,6,59,64 .”
InfluentialSelf-citationVià, M. D., Lazzaroni, F., Matera, A., Marella, A., Maeda, A., Magistris, C. D., Pettine, L., Solimando, A. G., Desantis, V., Peretti, G. M., et al. (2025) · Blood · doi:10.1182/blood.2024025643 · Cited by 15
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01312-x · Cited by 15
“Individuals with sMM are asymptomatic but possess a fl uctuat-ing risk of advancing to MM ranging from 10% per year for the fi rst 5 years, to 3% per year for the next 5 years, and 1% per year for the next 10 years [3].”
Timing of treatment of smoldering myeloma: early treatment
Mateos, M., & González‐Calle, V. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018021220 · Cited by 14
Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas
Singh, G. (2018) · Laboratory Medicine · doi:10.1093/labmed/lmy067 · Cited by 15
Henriot, B., Rouger, E., Rousseau, C., Escoffre‐Barbe, M., Sébillot, M., Bendavid, C., Minvielle, S., Avet‐Loiseau, H., Decaux, O., & Moreau, C. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1369 · Cited by 14
Wennmann, M., Hielscher, T., Kintzelé, L., Menze, B. H., Langs, G., Merz, M., Sauer, S., Kauczor, H., Schlemmer, H., Delorme, S., et al. (2020) · Cancers · doi:10.3390/cancers12092537 · Cited by 14
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
Schmidt, T. M., & Callander, N. S. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7660 · Cited by 15
Ríos, R., Puig, N., Algarín, E. M., Silva, J. L. G. D. V., Barbosa, N., Encinas, C., Hernández‐Rivas, J., Alonso, R., Campos, M. L., Rodríguez, T., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11112020 · Cited by 15
“MP levels ≥30 g/L in serum or ≥500 mg per 24 h in urine and/or 10–60% of MM cells in BM are indicative of SMM, that has an annual risk of progression to active MM of 10% during the first 5 years after diagnosis [7].”
BackgroundLevinson, S. S. (2010) · PubMed · Cited by 14
Vasco-Mogorrón, M. A., Campillo, J. A., Periago, A., Cabañas, V., Berenguer, M., García-Garay, M. C., Gimeno, L., Soto‐Ramírez, M. F., Martínez-Hernández, M. D., Muro, M., et al. (2021) · American Journal of Cancer Research · Cited by 16
Jurczyszyn, A., & Suska, A. (2019) · Reference Module in Biomedical Sciences · doi:10.1016/b978-0-12-801238-3.11412-6 · Cited by 13
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
Mohyuddin, G. R., Chakraborty, R., Cliff, E. R. S., & Derman, B. A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102272 · Cited by 14
“23 It is likely that contemporary patients with SMM (especially those who may be picked up due to screening and/or expanded use of highly sensitive assays 24 ) have an even lower risk of progression, and thus a lower potential bene fi t of treatment compared to earlier studies.”
Resultde Daniel, A., Rodríguez‐Lobato, L. G., Tovar, N., Cibeira, M. T., Moreno, D. F., Oliver‐Caldés, A., Isola, I., Lozano, E., Bladé, J., Rosiñol, L., et al. (2024) · HemaSphere · doi:10.1002/hem3.76 · Cited by 14
Patel, T. H., Bachu, R., Shrivastava, T., Alrawabdeh, J. A., Alzubi, M., Hastings, J., Dean, H., Schinke, C., Thanendrarajan, S., Zangari, M., et al. (2024) · Clinical Hematology International · doi:10.46989/001c.123608 · Cited by 13
Modeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems
Bottaro, A., Nasso, M. E., Stagno, F., Fazio, M., & Allegra, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136229 · Cited by 14
“It is widely acknowledged that multiple myeloma almost always develops following a previous stage known as monoclonal gammopathy of undetermined significance (MGUS), which progresses into active disease approximately 1% annually [8,9].”
Lightbody, E. D., Sklavenitis‐Pistofidis, R., Wu, T., Tsuji, J., Firer, D. T., Agius, M. P., Dutta, A. K., Barr, H., Kim, S., Alberge, J.-B., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01006-0 · Cited by 14
Hájek, R., Sandecká, V., Špıčka, I., Raab, M. S., Goldschmidt, H., Beck, S., Minařík, J., Pavlíček, P., Radocha, J., Heindorfer, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16572 · Cited by 13
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 14
Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa
Thokerunga, E., Ntege, C., & Ahmed, A. O. (2021) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-021-00088-3 · Cited by 13
“It is approximated that MGUS and SMM progress to full blown multiple myeloma at a rate of 1% and 10% per year respectively [33, 34].”
BackgroundLian, L., Wang, K., & Xu, S. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.755 · Cited by 13
“In another study, the median age at the time of diagnosis of MM was <64 years of age, which was the median age at the time of diagnosis of MM in the general population.(16) Our reported cases of SLE were diagnosed with MM at 59 and 58 years of age, respectively.”
BackgroundThomas, S. K., Suvorov, A., Noens, L. A., Rukavitsin, O., Fay, J. W., Wu, K. L., Zimmerman, T. M., de Velde, H. J. V., Bandekar, R. R., Puchalski, T. A., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2314-7 · Cited by 13
Current and Potential Epigenetic Targets in Multiple Myeloma
Pawlyn, C., Kaiser, M., Davies, F. E., & Morgan, G. J. (2014) · Epigenomics · doi:10.2217/epi.14.12 · Cited by 13
Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I
Бессмельцев, С. С. (2013) · Clinical oncohematology · doi:10.21320/2500-2139-2013-6-3-237-257 · Cited by 24
Späth, F., Wibom, C., Krop, E. J. M., Izarra, A., Johansson, A.-S., Bergdahl, I. A., Hultdin, J., Vermeulen, R. C. H., & Melin, B. S. (2019) · Haematologica · doi:10.3324/haematol.2019.216895 · Cited by 13
“Overview of the pre-diagnostic samples for each included case (1-65) with respect to disease status during the study period.”
Method
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.